Microbiome in Atopic Dermatitis Under Systemic Therapy

Recruiting now

Conditions studied: Atopic Dermatitis

In brief

The skin microbiome plays a role in the pathogenesis of atopic dermatitis. However, it is unclear whether the range of microbiota on the skin is the cause or consequence of atopic skin inflammation. The influence of new systemic therapies for the treatment of moderate to severe atopic dermatitis (such as biologics or Janus kinase inhibitors) on the skin microbiome is largely unknown. The main aim of this scientific exploratory study is to investigate whether and how the skin microbiome changes in patients with moderate to severe atopic dermatitis during systemic therapy. This not only allows new hypotheses to be generated on the pathogenesis of atopic dermatitis, but also new objective scales for the severity of atopic dermatitis can be developed.

Key facts

Study ID

NCT05099315

Run by

Charite University, Berlin, Germany

People needed

600

Starts

2019-10-01

Expected to finish

2025-12-31

Last updated by the study team

2025-02-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with moderate to severe atopic dermatitis
• Indication for systemic therapy

You may not qualify if…

• Patients under 18 years of age upon introducing systemic therapy
• Pregnant and lactating women

Where it is running

• Dpt of Dermatology and Allergology, Charité - Universitätsmedizin Berlin — Berlin, State of Berlin, Germany (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.